Myomo (MYO) Cash & Equivalents Growth (1y) (2017 - 2025)

Myomo (MYO) Cash & Equivalents Growth (1y) (2017 - 2025) Analysis & Trends

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr) Cash & Equiv. Growth (1y) (Qtr)
1 Abbott Laboratories 182.32 Bn 175.02 Bn 6.27 Bn 4.15%
2 Stryker 128.75 Bn 125.88 Bn 3.81 Bn 24.05%
3 Medtronic 107.83 Bn 98.61 Bn 6.41 Bn -12.13%
4 Boston Scientific 67.61 Bn 66.15 Bn 3.61 Bn 100.41%
5 Edwards Lifesciences 48.13 Bn 44.45 Bn 1.29 Bn -22.13%
6 Dexcom 28.26 Bn 27.14 Bn 750.30 Mn 23.57%
7 GE HealthCare Technologies 27.78 Bn 25.50 Bn 1.98 Bn -7.71%
8 Smith & Nephew 26.99 Bn 26.41 Bn - -10.02%
9 Koninklijke Philips 23.92 Bn 20.80 Bn 2.07 Bn 141.82%
10 Myomo 43.43 Mn 24.46 Mn - -40.57%

Historic Data

Download Data
DateValue
Dec 31, 2025 -40.57%
Sep 30, 2025 84.76%
Jun 30, 2025 150.00%
Mar 31, 2025 271.11%
Dec 31, 2024 260.16%
Sep 30, 2024 1.24%
Jun 30, 2024 -2.67%
Mar 31, 2024 -41.33%
Dec 31, 2023 28.53%
Sep 30, 2023 -6.60%
Jun 30, 2023 -41.32%
Mar 31, 2023 -28.43%
Dec 31, 2022 -65.56%
Sep 30, 2022 -41.30%
Jun 30, 2022 -25.68%
Mar 31, 2022 -25.49%
Dec 31, 2021 26.82%
Sep 30, 2021 -5.34%
Jun 30, 2021 28.31%
Mar 31, 2021 26.55%